Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Skin Diseases: early-phase trial registry
5 of 15 indexed Skin Diseases trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 5 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Skin Diseases: 15 US clinical trials tracked, 5 recruiting.
Skin Diseases is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 2 of these trials.
Enrollment posture brief
Registry condition skin-diseases
OPEN 5 | RECR 33% | LATE 2 | EARLY 9 | RANK #1140 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Skin Diseases lists 5 open slots (33% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Skin Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Skin Diseases is recruiting below its size-band peers.
5 of 15 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Skin Diseases trials is spread across many organizations.
Eli Lilly and Company accounts for 2 of 15 trials (13.3%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Skin Diseases enrolment sits around 90 participants.
Median target enrolment is 90 among the 15 trials that report a genuine target (sentinel values excluded). 8 of those (53.3%) plan for fewer than 100 participants.
-
Skin Diseases research is mostly interventional.
14 interventional and 1 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company
NCT05723198
Effects of Treatments on Atopic Dermatitis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT01631617
OCT Vibrography for Biomechanical Properties of Tissues
Massachusetts General Hospital
NCT05759780
Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders
Northwestern University
NCT05649098
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Oregon Health and Science University
NCT06563323
Trem-1 and Ultraviolet Radiation-induced Immune Suppression
University of Alabama at Birmingham
NCT05020496
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Cumberland Pharmaceuticals
NCT02682511
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
VA Office of Research and Development
NCT00847912
Impact of Teledermatology on Health Services Outcomes in the Department of Veterans Affairs
US Department of Veterans Affairs
NCT00488293
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
NCT01490632
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
Akros Pharma
NCT03832738
An Open Label Study for Palmar Hyperhydrosis
Pariser, Robert J., M.D.
NCT04906655
Joovvin' for Your Skin Health Study
ProofPilot
NCT04471896
Studying Normal Breast Tissue and Cancer Risk
National Cancer Institute (NCI)
NCT00341692
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Oregon Health and Science University
NCT04901325
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 7 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Skin Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Skin Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Skin Diseases page
15 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Skin Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Skin Diseases trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Skin Diseases condition card totals 15 registered trials; most-linked intervention Baricitinib; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.